Find the latest episode of "The Uncertain Hour" here. Listen
COVID-19

Vaccine supply chain bottlenecks eased, drugmakers tell Congress

Scott Tong Feb 23, 2021
Heard on:
HTML EMBED:
COPY
In vaccine making, one of the key bottlenecks is filling bottles quickly. Patrick T. Fallon/AFP via Getty Images
COVID-19

Vaccine supply chain bottlenecks eased, drugmakers tell Congress

Scott Tong Feb 23, 2021
Heard on:
In vaccine making, one of the key bottlenecks is filling bottles quickly. Patrick T. Fallon/AFP via Getty Images
HTML EMBED:
COPY

Three hundred million doses from Pfizer. Three hundred million from Moderna. One hundred million from Johnson & Johnson. One hundred million from Novavax.

One by one, the chief executives of America’s COVID-19 vaccine makers promised in congressional testimony to deliver the doses promised to the U.S. government by summer. The projections of confidence come after months of supply chain challenges and companies falling short of year-end projections for 2020.

What changed?

In vaccine making, one of the key bottlenecks is, well, the bottles. The vials that contain the drugs have to be filled, and that can only go so fast.

“It’s simply the throughput of finding the facilities that are able to fill,” said Clem Lewin, an independent vaccine consultant. “You need to qualify them because these are highly regulated products where safety is critical.”

But he said drugmakers that normally compete are now actually helping one another. For instance, Sanofi, whose vaccine is not ready for production, is filling vials for Pfizer. As is Novartis.

Perhaps the drug companies feel they have to collaborate.

“There is some discussion that they’re kind of reluctant,” said Anna Nagurney, supply chain scholar at the University of Massachusetts at Amherst. “But I think sooner or later if they’re promising to double the capacity, you have to keep your promises.”

Another efficiency gain is Moderna’s plan to squeeze 15 doses into a vial, instead of 10, Nagurney said. Some vaccine developers have struck deals with contract manufacturers for so-called fill-and-finish work.

But not every challenge has been solved.

Vaccines from Moderna and Pfizer, which deliver genetic instructions to produce virus proteins that trigger immune system responses, require special compounds called lipids. Certain lipids provide exterior protection for the RNA but were only manufactured in boutique quantities before the pandemic.

“We had never imagined that we were going to need these lipid nanoparticles in the quantities that we now need them,” said Prashant Yadav, supply chain scholar and fellow at the Center for Global Development. “Which means there are very few suppliers in the world, one or two.”

Vaccine company CEOs said they have found new lipid sources, but the specific details of these transactions are vague because supply chains are secret.

“If you’ve got a line on some really good material, or a supplier who is reliable and can provide at scale, you don’t want everybody else to know about that,” said Derek Lowe, a drug discovery researcher.

Two more doses of good news: Johnson & Johnson expects its vaccine to receive Food and Drug Administration authorization any day. And the Novavax version, which is expected to be scaled up quickly and affordably, is assumed to be close behind.



COVID-19 Economy FAQs

So what’s up with “Zoom fatigue”?

It’s a real thing. The science backs it up — there’s new research from Stanford University. So why is it that the technology can be so draining? Jeremy Bailenson with Stanford’s Virtual Human Interaction Lab puts it this way: “It’s like being in an elevator where everyone in the elevator stopped and looked right at us for the entire elevator ride at close-up.” Bailenson said turning off self-view and shrinking down the video window can make interactions feel more natural and less emotionally taxing.

How are Americans spending their money these days?

Economists are predicting that pent-up demand for certain goods and services is going to burst out all over as more people get vaccinated. A lot of people had to drastically change their spending in the pandemic because they lost jobs or had their hours cut. But at the same time, most consumers “are still feeling secure or optimistic about their finances,” according to Candace Corlett, president of WSL Strategic Retail, which regularly surveys shoppers. A lot of people enjoy browsing in stores, especially after months of forced online shopping. And another area expecting a post-pandemic boost: travel.

What happened to all of the hazard pay essential workers were getting at the beginning of the pandemic?

Almost a year ago, when the pandemic began, essential workers were hailed as heroes. Back then, many companies gave hazard pay, an extra $2 or so per hour, for coming in to work. That quietly went away for most of them last summer. Without federal action, it’s mostly been up to local governments to create programs and mandates. They’ve helped compensate front-line workers, but they haven’t been perfect. “The solutions are small. They’re piecemeal,” said Molly Kinder at the Brookings Institution’s Metropolitan Policy Program. “You’re seeing these innovative pop-ups because we have failed overall to do something systematically.”

Read More

Collapse

Marketplace is on a mission.

We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.

Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?

Your donation is critical to the future of public service journalism. Support our work today – for as little as $5 – and help us keep making people smarter.